相似文献
1
Adoptive B-cell transfer mouse model of human myeloma.
Leukemia. 2016 Apr;30(4):962-6. doi: 10.1038/leu.2015.197. Epub 2015 Jul 23.
2
Role of interleukin-6 in the pathogenesis of murine plasmacytoma and human multiple myeloma.
Am J Pathol. 1997 Sep;151(3):647-9.
3
Interleukin-18 inhibits lodging and subsequent growth of human multiple myeloma cells in the bone marrow.
Oncol Rep. 2002 Nov-Dec;9(6):1237-44.
4
B cell compartments in multiple myeloma: flow cytometric analysis of their labelling indices and Bcl-2 protein expression.
Hematol Cell Ther. 1998 Feb;40(1):11-6.
5
Evaluation of Bcl-2/B cell transgenic mice (B6) for hybridoma production.
Hybridoma. 1996 Oct;15(5):365-71. doi: 10.1089/hyb.1996.15.365.
6
7
Pathogenesis of myeloma bone disease.
Blood Cells Mol Dis. 2004 Mar-Apr;32(2):290-2. doi: 10.1016/j.bcmd.2004.01.001.
8
Liposomes of phosphatidylcholine and cholesterol induce an M2-like macrophage phenotype reprogrammable to M1 pattern with the involvement of B-1 cells.
Immunobiology. 2014 Jun;219(6):403-15. doi: 10.1016/j.imbio.2014.01.006. Epub 2014 Feb 3.
9
Bone disease in multiple myeloma.
Br J Haematol. 1998 Dec;103(4):902-10. doi: 10.1046/j.1365-2141.1998.01082.x.
10
Signalling and survival pathways in multiple myeloma.
Eur J Cancer. 2006 Jul;42(11):1574-80. doi: 10.1016/j.ejca.2005.12.026. Epub 2006 Jun 22.
引用本文的文献
1
Laboratory Mice - A Driving Force in Immunopathology and Immunotherapy Studies of Human Multiple Myeloma.
Front Immunol. 2021 Jun 2;12:667054. doi: 10.3389/fimmu.2021.667054. eCollection 2021.
2
Mouse tumor susceptibility genes identify drug combinations for multiple myeloma.
J Cancer Metastasis Treat. 2020;6. doi: 10.20517/2394-4722.2020.40. Epub 2020 Jul 26.
3
Transgenic mouse model of IgM lymphoproliferative disease mimicking Waldenström macroglobulinemia.
Blood Cancer J. 2016 Nov 4;6(11):e488. doi: 10.1038/bcj.2016.95.
4
FOXM1 is a therapeutic target for high-risk multiple myeloma.
Leukemia. 2016 Apr;30(4):873-82. doi: 10.1038/leu.2015.334. Epub 2015 Dec 9.
本文引用的文献
1
GP130 activation induces myeloma and collaborates with MYC.
J Clin Invest. 2014 Dec;124(12):5263-74. doi: 10.1172/JCI69094. Epub 2014 Nov 10.
2
The tumor microenvironment is the main source of IL-6 for plasma cell tumor development in mice.
Leukemia. 2015 Jan;29(1):233-7. doi: 10.1038/leu.2014.260. Epub 2014 Sep 3.
3
Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy.
Cancer Cell. 2014 Jan 13;25(1):91-101. doi: 10.1016/j.ccr.2013.12.015.
4
(18)F-FDG-PET/CT imaging in an IL-6- and MYC-driven mouse model of human multiple myeloma affords objective evaluation of plasma cell tumor progression and therapeutic response to the proteasome inhibitor ixazomib.
Blood Cancer J. 2013 Nov 29;3(11):e165. doi: 10.1038/bcj.2013.61.
5
A novel rapid-onset high-penetrance plasmacytoma mouse model driven by deregulation of cMYC cooperating with KRAS12V in BALB/c mice.
Blood Cancer J. 2013 Nov 1;3(11):e156. doi: 10.1038/bcj.2013.53.
6
MYD88 L265P somatic mutation in Waldenström's macroglobulinemia.
N Engl J Med. 2012 Aug 30;367(9):826-33. doi: 10.1056/NEJMoa1200710.
7
Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma.
Blood. 2012 Aug 30;120(9):1877-87. doi: 10.1182/blood-2011-12-396853. Epub 2012 Jun 11.
8
The genetic architecture of multiple myeloma.
Nat Rev Cancer. 2012 Apr 12;12(5):335-48. doi: 10.1038/nrc3257.
9
Antitumor activity of the investigational proteasome inhibitor MLN9708 in mouse models of B-cell and plasma cell malignancies.
Clin Cancer Res. 2011 Dec 1;17(23):7313-23. doi: 10.1158/1078-0432.CCR-11-0636. Epub 2011 Sep 8.
10
BRAF mutations in hairy-cell leukemia.
N Engl J Med. 2011 Jun 16;364(24):2305-15. doi: 10.1056/NEJMoa1014209. Epub 2011 Jun 11.
Zotero 插件